Generic Cymbalta Recall Class Action Settlement

Consumers who purchased generic duloxetine between August 4, 2020, and May 22, 2025, may be eligible to receive a cash payment from a class action settlement.

Individuals who purchased generic duloxetine manufactured for Breckenridge Pharmaceutical Inc. during the qualifying period may submit a claim to receive a single payment of up to $7.50 or $10 per prescription, depending on the product’s recall status.

The lawsuit alleges that Breckenridge’s generic duloxetine contained an impurity known as n-nitroso-duloxetine (NDLX), a nitrosamine that may be harmful under certain conditions. Plaintiffs argue that the presence of NDLX rendered the product unlawful for sale and economically worthless, causing financial losses.

This settlement compensates for economic losses only and does not address personal injury claims.

Who Is Eligible?

Class members include:

• Individuals in the United States who purchased Breckenridge duloxetine for personal or household use between August 4, 2020, and May 22, 2025.
• The class includes both recalled and non-recalled duloxetine products.

The settlement website provides a list of recalled lots, including expiration dates, NDC numbers, and lot numbers.

Who Is Excluded?

Consumers who did not pay out-of-pocket for Breckenridge duloxetine are excluded, such as those whose prescriptions were fully covered by insurance or provided at no cost.

Settlement Payment Amounts

Class members may claim only one of the following:

Non-recall tier:

• $5 total
• For purchases of Breckenridge duloxetine not subject to recall.

Recall tier:

• $7.50 total
• For purchases subject to a recall before May 22, 2025.

Recall-plus tier:

• $10 per recalled prescription
• For prescriptions subject to recall and not used due to the recall.

How to Submit a Claim

Claims must be submitted by December 27, 2025.
Class members may file online or download the personalized claim form to print and mail.

Mailing address:
Boyer v. Breckenridge Pharmaceuticals Claims Administrator
P.O. Box 301132
Los Angeles, CA 90030-1132

Proof Requirements

Proof is required for all claim types:

Non-recall tier:

• Pharmacy receipt, pharmacy records, or insurance records showing purchase date and cost.

Recall tier:

• Proof of purchase plus pharmacy documentation showing lot number or expiration date and NDC of the recalled product.

Recall-plus tier:

• All proof required for recall tier claims.
• Must also return unused recalled duloxetine or submit a signed certification confirming it was not used.

Settlement Fund Details

The settlement fund includes:

• Settlement administration costs: To be determined
• Attorneys’ fees: $150,000
• Service award: $1,500
• Payments to approved claimants: Amount depends on the number of valid claims filed

Important Dates

• Opt-out deadline: August 18, 2025
• Fairness hearing: September 23, 2025
• Claim filing deadline: December 27, 2025

When Will Payments Be Sent?

Payments will be issued after the settlement administrator reviews all claims and final claim processing is completed.

Why Was This Settlement Reached?

The lawsuit alleges Breckenridge sold duloxetine containing a harmful impurity, rendering the product economically worthless and violating federal regulations.

Breckenridge denies the allegations but agreed to settle to avoid ongoing litigation costs and risks.

Award: Varies
Deadline: December 27, 2025